Compare KSS & BLFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KSS | BLFS |
|---|---|---|
| Founded | 1962 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 1995 | 2013 |
| Metric | KSS | BLFS |
|---|---|---|
| Price | $16.42 | $36.17 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 15 | 1 |
| Target Price | $15.31 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 3.9M | 814.8K |
| Earning Date | 05-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.58% | N/A |
| EPS Growth | ★ 142.86 | 77.27 |
| EPS | ★ 1.18 | 0.94 |
| Revenue | N/A | ★ $96,214,000.00 |
| Revenue This Year | N/A | $19.73 |
| Revenue Next Year | $0.21 | $17.82 |
| P/E Ratio | ★ $13.89 | $38.51 |
| Revenue Growth | N/A | ★ 16.97 |
| 52 Week Low | $11.38 | $17.86 |
| 52 Week High | $25.22 | $38.10 |
| Indicator | KSS | BLFS |
|---|---|---|
| Relative Strength Index (RSI) | 38.16 | 59.51 |
| Support Level | $15.87 | $23.66 |
| Resistance Level | $20.00 | $38.10 |
| Average True Range (ATR) | 0.92 | 0.94 |
| MACD | -0.22 | -0.22 |
| Stochastic Oscillator | 5.11 | 60.47 |
Kohl's is the second-largest traditional US department store company by sales. It has about 1,150 stores in 49 states and offers moderately priced private-label (31% of 2025 sales) and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most (about 80%) of its stores are in strip centers. Kohl's also has a large digital sales operation (29% of 2025 sales). Women's apparel is the retailer's largest category, having generated 24% of its 2025 sales. Kohl's is headquartered in Menomonee Falls, Wisconsin, and was founded in 1962.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.